Hepatocellular Carcinoma — MCQs
A patient with a history of alcohol dependence syndrome presents with sudden and unintentional weight loss. What is the most likely diagnosis?
A 60-year-old male with a history of cirrhosis presents with a 4 cm hepatocellular carcinoma (HCC) located in segment VII of the liver. Considering the patient has Child-Pugh A liver function, which clinical factors are most critical in deciding between liver resection and radiofrequency ablation (RFA)?
Which of the following is true regarding extended criteria donors for liver transplantation?
What does the MELD diagnostic score predict in patients awaiting liver transplantation?
All of the following modalities can be used for in situ ablation of liver secondaries, except:
What is the treatment of choice for medullary carcinoma of the thyroid?
A dentist who got infected with Hepatitis B has recovered from it for the last 3 months. His laboratory tests are normal, but he is not allowed to treat patients. He is known as?
Treatment of choice for mucinous carcinoma of the gall bladder in the early stage is -
Which of the following is not a risk factor for cholangiocarcinoma?
What is the most important presenting feature of periampullary carcinoma?
Hepatocellular Carcinoma Indian Medical PG Practice Questions and MCQs
Question 1: A patient with a history of alcohol dependence syndrome presents with sudden and unintentional weight loss. What is the most likely diagnosis?
- A. Hepatic adenoma
- B. Cholangiocarcinoma
- C. Hepatocellular carcinoma (Correct Answer)
- D. Alcoholic hepatitis
Explanation: ***Hepatocellular carcinoma*** - The **alpha-fetoprotein (AFP)** level of **600 ng/mL** is significantly elevated, suggesting a diagnosis of hepatocellular carcinoma, especially in a patient with a history of **alcohol dependence syndrome** [1]. - The **AST/ALT ratio of 0.5** indicates significant liver damage, commonly seen in chronic liver disease leading to **hepatocellular cancer**. *Alcoholic hepatitis* - Typically presents with **elevated AST and ALT**, usually with a ratio >2:1, which is not the case here [2]. - May cause weight loss, as alcoholic patients often lose weight due to self-neglect and poor dietary intake, but the **elevated AFP** is not characteristic of merely alcoholic hepatitis [3]. *Cholangiocarcinoma* - This type of cancer primarily presents with **biliary obstruction** symptoms, such as jaundice, which is not indicated here given **normal bilirubin levels**. - Does not typically lead to such high levels of **AFP**, making it less likely with the provided lab results. *Hepatic adenoma* - More commonly associated with **oral contraceptive use** or anabolic steroid use, not primarily alcohol dependence. - AFP levels are usually normal or only mildly elevated in hepatic adenoma, making this option less viable with an **AFP level of 600 ng/mL**.
Question 2: A 60-year-old male with a history of cirrhosis presents with a 4 cm hepatocellular carcinoma (HCC) located in segment VII of the liver. Considering the patient has Child-Pugh A liver function, which clinical factors are most critical in deciding between liver resection and radiofrequency ablation (RFA)?
- A. Tumor size, location, liver function, and portal hypertension status (Correct Answer)
- B. Presence of comorbidities and performance status
- C. Tumor vascular invasion and metastasis
- D. Patient’s age and overall health status
Explanation: ***Tumor size, location, liver function, and portal hypertension status*** - **Tumor size and location** are critical for resectability and RFA feasibility, as HCCs larger than 3-5 cm or located near major vessels/bile ducts may be harder to ablate or resect safely. - **Liver function (Child-Pugh A)** helps assess the liver's reserve to tolerate resection, while the presence of **portal hypertension** indicates a higher risk of post-resection liver decompensation, favoring RFA. *Presence of comorbidities and performance status* - While important for overall surgical risk assessment (ASA score), **comorbidities** and **performance status** are general considerations and not the primary factors differentiating between liver resection and RFA for HCC in a patient with good liver function. - These factors influence the patient's ability to undergo any intervention, but they don't directly guide the choice between a local ablative therapy and surgical removal based on tumor or liver characteristics. *Tumor vascular invasion and metastasis* - The presence of **vascular invasion** or **distant metastasis** generally indicates advanced disease, precluding both curative resection and RFA, pushing towards systemic therapies or palliative care. - These are factors that determine if **curative treatment** is an option at all, rather than helping to choose between two curative local treatments (resection vs. RFA). *Patient’s age and overall health status* - **Age** is less of a direct contraindication for either procedure in itself, especially in a 60-year-old with Child-Pugh A, as physiological age and performance status are more relevant than chronological age. - While **overall health status** is considered, it overlaps with comorbidities and performance status and is not as discriminative as tumor-specific factors or liver physiology in choosing between resection and RFA for HCC.
Question 3: Which of the following is true regarding extended criteria donors for liver transplantation?
- A. Donors with well-controlled diabetes mellitus
- B. Hepatitis C antibody positive donors
- C. Donors with significant uncontrolled comorbidities
- D. Donors aged >60 years with no significant comorbidities (Correct Answer)
Explanation: ***Donors aged >60 years with no significant comorbidities*** - **Advanced donor age** is a key characteristic of an extended criteria donor (ECD), especially when coupled with other factors like **ischemic time** or comorbidities. - While age alone might not prohibit donation, it puts the donor liver into the ECD category, requiring careful recipient selection and possibly increasing the risk of **post-transplant complications**. *Donors with well-controlled diabetes mellitus* - **Well-controlled diabetes mellitus** in a donor does not automatically classify them as an extended criteria donor, if there are no other significant associated comorbidities or organ damage. - The focus is generally on signs of significant end-organ damage or poorly controlled disease that could impact graft function. *Hepatitis C antibody positive donors* - **Hepatitis C antibody positive donors** are traditionally considered extended criteria donors and remain classified as such. - However, with the advent of highly effective **direct-acting antiviral (DAA) therapies**, HCV-positive organs can now be safely transplanted into both HCV-positive and HCV-negative recipients with excellent outcomes. - While still technically ECD, the clinical significance has diminished significantly with modern treatment availability, making **donor age >60 years** the more universally recognized ECD criterion in current practice. *Donors with significant uncontrolled comorbidities* - **Significant uncontrolled comorbidities** would generally render a donor **unsuitable for donation**, rather than classify them as an extended criteria donor. - Extended criteria typically refer to factors that increase risk but are still acceptable under specific circumstances, whereas uncontrolled comorbidities often pose too high a risk for successful transplantation.
Question 4: What does the MELD diagnostic score predict in patients awaiting liver transplantation?
- A. Higher score - less mortality risk
- B. Predicts mortality risk for a 60 day period
- C. It is a 4 to 60 scale
- D. Predicts mortality in patients waiting for liver transplant (Correct Answer)
Explanation: ***Predicts mortality in patients waiting for liver transplant*** - The **Model for End-Stage Liver Disease (MELD)** score was developed to predict **mortality risk** in patients with severe liver disease [1]. - It is crucial for **prioritizing patients** on the liver transplant waiting list, ensuring those with the greatest immediate need receive organs first. *Higher score - less mortality risk* - A **higher MELD score** indicates **more severe liver disease** and a **higher risk of mortality**, not less [1]. - The scoring system is designed to identify patients who are most critically ill and therefore have a greater need for transplantation [1]. *Predicts mortality risk for a 60 day period* - The MELD score was originally developed to predict **3-month (90-day) mortality** in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS) procedures. - While it's used for short-term prediction, 60 days is not the standard predictive period. *It is a 4 to 60 scale* - The MELD score typically ranges from **6 to 40**, although extreme clinical conditions can lead to scores outside this range in rare cases. - A score of 4 would be unusually low and not reflective of the calculated range based on its components.
Question 5: All of the following modalities can be used for in situ ablation of liver secondaries, except:
- A. Radiofrequency
- B. Ultrasonic waves
- C. Alcohol (Correct Answer)
- D. Cryotherapy
Explanation: ***Alcohol*** - While **percutaneous ethanol injection (PEI)** can be used for **ablation of small hepatocellular carcinomas**, it is generally not a primary modality for **in situ ablation of liver secondaries** due to less predictable ablation margins and diffusion. - Its use is more prevalent for very small, localized primary tumors or for cystic lesions, rather than for metastatic disease where more precise and extensive ablation is often required. *Radiofrequency* - **Radiofrequency ablation (RFA)** uses high-frequency electrical currents to generate heat, causing **coagulation necrosis** of tumor cells within the liver. - It is a widely accepted and effective modality for **in situ ablation of liver secondaries**, particularly for lesions up to 3-5 cm. *Ultrasonic waves* - **High-intensity focused ultrasound (HIFU)** uses focused ultrasonic waves to generate heat and destroy tumor tissue, and is an evolving non-invasive method for **liver tumor ablation**. - HIFU causes **thermal ablation** leading to coagulative necrosis and can be used for both primary and secondary liver tumors. *Cryotherapy* - **Cryoablation** involves the use of extreme cold to destroy tumor cells, typically by inserting probes into the tumor to create **ice balls**. - It is an effective method for **in situ ablation of liver secondaries**, causing **cellular injury** and **necrosis** through direct cold effects and microvascular thrombosis.
Question 6: What is the treatment of choice for medullary carcinoma of the thyroid?
- A. I-131 ablation
- B. Total thyroidectomy (Correct Answer)
- C. Partial thyroidectomy
- D. Hemithyroidectomy
Explanation: ***Total thyroidectomy*** - This is the **treatment of choice for medullary thyroid carcinoma (MTC)** due to its multifocal nature and high propensity for lymph node metastasis - **Complete surgical resection** (often with central compartment neck dissection) provides the best chance for cure by removing all thyroid tissue and involved lymph nodes - MTC arises from **parafollicular C cells** (calcitonin-producing cells) and frequently involves both lobes, making total thyroidectomy essential *Partial thyroidectomy* - This procedure removes only a portion of the thyroid gland, which is **insufficient for MTC** given its tendency for multifocality and bilateral involvement - Leaves residual thyroid tissue that could harbor undetected disease or develop future recurrences - Does not adequately address the aggressive nature of MTC *I-131 ablation* - **Radioactive iodine therapy** is effective for differentiated thyroid cancers (papillary and follicular) that take up iodine - MTC originates from **parafollicular C cells that do not concentrate iodine**, making I-131 ablation completely ineffective - This is a key distinguishing feature of MTC from other thyroid malignancies *Hemithyroidectomy* - This procedure removes only one thyroid lobe, which is **inadequate for MTC** - Risks leaving behind primary tumor in the contralateral lobe or occult bilateral disease - Fails to address the multifocal nature of MTC, particularly in hereditary cases (MEN 2A, MEN 2B, familial MTC)
Question 7: A dentist who got infected with Hepatitis B has recovered from it for the last 3 months. His laboratory tests are normal, but he is not allowed to treat patients. He is known as?
- A. Chronic carrier
- B. Convalescent carrier (Correct Answer)
- C. Active carrier
- D. Paradoxical carrier
Explanation: ***Convalescent carrier*** - A **convalescent carrier** is someone who has recovered clinically from an acute infection but continues to harbor and can transmit the pathogen during the recovery period, typically for **weeks to a few months** after apparent recovery. - In Hepatitis B, a convalescent carrier may still have **HBsAg positivity** despite normal liver function tests and clinical recovery, and can transmit the virus during this period. - The scenario describes a dentist who recovered **3 months ago** with normal laboratory tests but is still restricted from treating patients, indicating he remains in the **convalescent carrier phase** and has not yet reached the 6-month threshold for chronic carrier status. - This is why healthcare workers in this phase are temporarily restricted from exposure-prone procedures to prevent transmission. *Chronic carrier* - A **chronic carrier** state for Hepatitis B is defined by the persistence of **HBsAg** (Hepatitis B surface antigen) for **more than 6 months** after acute infection. - While chronic carriers can have normal liver function tests, the key distinguishing feature is the **duration >6 months**, which does not match the **3-month timeline** described in this question. - The dentist has not yet met the temporal criterion for chronic carrier classification. *Active carrier* - The term **active carrier** is not a standard epidemiological classification in medical literature and lacks precise definition. - While both convalescent and chronic carriers can actively transmit disease, the term "active" does not specify the **phase or duration** of the carrier state, which is critical for classification. *Paradoxical carrier* - There is no recognized medical definition for **paradoxical carrier** in epidemiology or infectious disease literature. - This is a distracter with no clinical relevance to carrier state classification.
Question 8: Treatment of choice for mucinous carcinoma of the gall bladder in the early stage is -
- A. Simple cholecystectomy (Correct Answer)
- B. Extended cholecystectomy
- C. Cholecystectomy with wedge resection of liver
- D. Chemotherapy only
Explanation: ***Simple cholecystectomy*** - For **early-stage (T1a) mucinous carcinoma of the gallbladder**, **simple cholecystectomy** is the treatment of choice - T1a disease (tumor confined to mucosa) has an excellent prognosis with **5-year survival >90%** after simple cholecystectomy alone - Extended resection offers **no survival benefit** for T1a disease and increases surgical morbidity - If incidentally discovered post-cholecystectomy with negative margins, no further surgery is needed *Extended cholecystectomy* - **Extended cholecystectomy** (cholecystectomy + liver segments IVb/V resection + portal lymphadenectomy) is indicated for **T2 or higher stage** disease (tumor invading muscularis propria or beyond) - This is **not** the treatment for early-stage disease as it increases morbidity without survival benefit - Reserved for more advanced tumors with deeper invasion *Cholecystectomy with wedge resection of liver* - This describes a component of extended cholecystectomy and is similarly indicated for **T2+ disease**, not early-stage - Wedge resection aims to achieve negative margins when tumor extends beyond the gallbladder wall - Not appropriate for early-stage mucinous carcinoma confined to mucosa *Chemotherapy only* - **Chemotherapy alone** is not curative for early-stage gallbladder carcinoma - Surgery remains the primary curative treatment for resectable disease - Chemotherapy is reserved for advanced, metastatic, or unresectable disease as palliative treatment
Question 9: Which of the following is not a risk factor for cholangiocarcinoma?
- A. Thorotrast
- B. Radon
- C. Dioxin
- D. Aflatoxin (Correct Answer)
Explanation: ***Aflatoxin*** - **Aflatoxin** is a potent **hepatocarcinogen** produced by *Aspergillus* species that is specifically and strongly linked to **hepatocellular carcinoma (HCC)** [1], NOT cholangiocarcinoma. - This is the **most clearly unrelated** risk factor to cholangiocarcinoma among the options, as its carcinogenic mechanism targets hepatocytes specifically [1], [2]. - It contaminates crops in warm, humid regions and is a well-established cause of liver cancer in endemic areas [1]. *Thorotrast* - **Thorotrast** (thorium dioxide) was a radioactive contrast agent used until the 1950s that **IS a known risk factor** for cholangiocarcinoma. - Due to prolonged retention in the liver and biliary system, it significantly increases the risk of both **cholangiocarcinoma** and **hepatic angiosarcoma** [3]. - Its use was discontinued precisely because of its strong carcinogenic potential. *Radon* - **Radon** is a naturally occurring radioactive gas that is primarily and overwhelmingly associated with **lung cancer** from inhalation exposure. - While a potent carcinogen, it has **no established epidemiological link** to cholangiocarcinoma due to its route of exposure and target organ. *Dioxin* - **Dioxins** are environmental pollutants with documented carcinogenic effects. - While some studies have explored potential links to various cancers, dioxin is **not recognized as an established risk factor** for cholangiocarcinoma in major medical references. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 876-877. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 331-332. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 216-217.
Question 10: What is the most important presenting feature of periampullary carcinoma?
- A. Jaundice (Correct Answer)
- B. Abdominal Pain
- C. Unintentional Weight Loss
- D. Palpable Abdominal Mass
Explanation: ***Jaundice*** - **Painless obstructive jaundice** is the hallmark symptom, occurring early due to the tumor's proximity to the common bile duct. - The obstruction of bile flow leads to the accumulation of **bilirubin**, causing yellow discoloration of the skin and eyes. *Abdominal Pain* - While **abdominal pain** can occur, it is often a later symptom and is less specific than jaundice for early diagnosis. - Pain typically arises from tumor growth, invasion of surrounding structures, or pancreatic involvement. *Unintentional Weight Loss* - **Unintentional weight loss** is a common constitutional symptom of many advanced malignancies, including periampullary carcinoma. - However, it usually manifests at a later stage and is not the initial, specific presenting feature that prompts investigation. *Palpable Abdominal Mass* - A **palpable abdominal mass** is rare in early periampullary carcinoma, as these tumors are typically small and deeply seated. - Its presence usually indicates advanced disease with significant tumor burden or metastasis.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free